Mastering the correct usage and dosage of bulevirtide is fundamental to ensuring antiviral efficacy and medication safety. Patients must strictly adhere to the standard dose, follow standardized procedures, and properly manage special situations to fully realize the drug's therapeutic effects.
I. Standard Dosing Regimen
1. Recommended Dose
(1) The recommended dose of bulevirtide in adult patients is 8.5 mg once daily.
(2) The route of administration is subcutaneous injection, with the solution injected into the subcutaneous tissue of the abdomen, thigh, or upper arm (when administered by another person).
2. Duration of Therapy
(1) Treatment should be continued as long as the patient achieves virologic or biochemical response.
(2) The optimal duration of therapy has not been established and should be dynamically assessed by the physician on an individual basis.
3. Management of Underlying Disease
Hepatitis D virus relies on hepatitis B virus for replication; therefore, during bulevirtide therapy, patients should continue nucleos(t)ide analogue antiviral treatment for chronic hepatitis B to achieve coordinated control of the dual infection.
II. Standard Operating Procedures
1. Reconstitution Method
(1) The drug is provided as a lyophilized powder and must be reconstituted with 1 mL of sterile water for injection before use.
(2) After reconstitution, gently swirl the vial until the powder is completely dissolved and the solution becomes clear, free of visible particles or aggregates.
(3) Aseptic technique must be maintained during reconstitution. Before use, inspect the solution for discoloration or insoluble particulates.
2. Injection Procedure
(1) Injection sites should be the abdomen (avoiding the 2.5 cm area around the navel), the anterolateral thigh, or the back of the upper arm.
(2) Rotate injection sites each time, avoiding the same site on two consecutive days to minimize local reactions.
(3) Cleanse the skin with an alcohol swab before injection and allow it to air dry before inserting the needle.
(4) If bleeding occurs after injection, apply gentle pressure with a cotton ball for a moment; do not rub.
2. Immediate Use Principle
(1) The reconstituted solution must be used immediately; do not refrigerate or store for the next injection.
(2) Any unused reconstituted solution and the vial should be discarded.
III. Management of Special Situations
1. Missed Dose
(1) If a dose is missed, administer it as soon as remembered.
(2) However, if it is nearly time for the next scheduled dose, skip the missed dose and resume the regular dosing schedule.
(3) Do not administer a double dose to make up for the missed one.
2. Basis for Dose Adjustment
(1) No dose adjustment of bulevirtide is recommended in adult patients with different renal or hepatic function status.
(2) Patients with mild to severe renal impairment or mild hepatic impairment (Child-Pugh A) may receive the standard dose.
(3) For patients with moderate to severe hepatic impairment or end-stage renal disease, data are limited; treatment should be evaluated and administered under close physician monitoring.
3. Risks of Treatment Interruption
(1) Unauthorized interruption of bulevirtide therapy may lead to severe acute exacerbation of hepatitis D and hepatitis B viruses.
(2) Therefore, do not discontinue the drug without consulting your physician and obtaining explicit guidance.
(3) Even if the physician recommends discontinuation, close follow-up monitoring for at least 6 months after cessation is required.
